1. Advance

We have a diversified and balanced clinical development pipeline, covering multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

The company also has a vaccine platform discovering and developing glycoconjugate vaccines containing synthetic antigenic glycan molecules with and without a carrier protein to prevent infection.

The pipeline comprises more than 10 compounds, with half in late-stage development. The development of an innovative compound into a future therapy is a complex undertaking, which inevitably involves an element of risk. With our scientific, data-driven approach helping to mitigate risk at each step, we have already brought two products to the market, QUVIVIQ in the US and Europe, and PIVLAZ® in Japan (license rights later assigned to Nxera Pharma (previously known as Sosei Heptares) for Japan, South Korea and APAC (excluding China)), with aprocitentan currently approved in the US under the tradename TRYVIO™  and undergoing regulatory assessment in the EU.

Idorsia-led Portfolio

Partner-led Portfolio

We now aim to broaden the availability of our products by launching QUVIVIQ in additional markets and bring additional products from our late-stage development pipeline, such as lucerastat, selatogrel, and cenerimod, to the market in the near term.

“With patients at the heart of our process, our key assets have the potential to transform treatment in the target indications.”
— Alberto Gimona, Head of Global Clinical Development and Medical Affairs

2. Launch

We have taken a simple, efficient approach to our first product launches, utilizing shared, best in class platforms and ways of working that enable fast decision-making and cost effective growth. We will continue to focus on transforming treatment in underserved markets, such as insomnia, using scientific and medical evidence to engage effectively with experts in the field and with payors. We plan to remain flexible and nimble in the way we commercialize our portfolio. We have built the core capabilities required to successfully launch our products, while also entering into partnerships where we need support to reach a primary care market.

We have established commercial operations in the US and the major European markets, with experienced leadership teams and strategic locations. We have also established a robust and lean global supply chain function to ensure consistent supplies of our innovative medicines to patients.

“Idorsia has the ideal constellation for bringing successful medicines to the market.”

— André C. Muller, CEO

3. Profitability

We believe that we have the potential to generate significant revenues from our innovative portfolio, which now includes a product on the market in the US and several European countries, and another product under review by US and EU health authorities.

To maximize the medical value of our discoveries and to provide a source of liquidity in the short to medium term, we have entered into several collaborative partnerships with pharmaceutical companies. These include development, commercialization, and revenuesharing agreements, under which we are eligible to receive milestone payments based on the progress of the development compound in question.

Furthermore, with several unencumbered assets in clinical development, additional contract revenue from partnerships and/or out-licensing remains an option for us.

“We have a diverse pipeline with unique assets that have significant potential for patients. We must invest in this pipeline in order to make Idorsia a profitable company, in a sustainable manner.”

— Arno Groenewoud, CFO

Our strategy to reach profitability relies on dual revenue streams...

Sales from our commercial products

We will generate our own sales income, starting with QUVIVIQ™ (daridorexant) in the US and Europe.

Sales from our marketed products will be followed by other products from our late-stage clinical pipeline:

  • Aprocitentan is only approved in the US under the tradename TRYVIO™ where it will be made available later in 2024. Market authorization is under review in other countries.
  • Aprocitentan marketing applications are under review by health authorities in the EU.
  • We are developing lucerastat for Fabry disease.
  • Cenerimod is in development for systemic lupus erythematosus.
  • Selatogrel is in development for suspected acute myocardial infarction.

Our rich pipeline means that we will have substantial opportunities to leverage our fit-for-purpose commercial organization.

Revenues from royalties & revenue streams

Several of our partnerships include development, commercialization and revenue-sharing agreements, under which we are eligible to receive milestone payments based on the progress of the development compound in question.

Cenerimod and Selatogrel:

Idorsia has entered into agreements for a significant global research and development collaboration with Viatris Inc., a global healthcare company, for the global development and commercialization of two Phase 3 assets – selatogrel and cenerimod.

T-type calcium channel blocker:

Idorsia entered into a global license agreement with Neurocrine Biosciences for the development and commercialization of ACT-709478, Idorsia’s potent, selective, orally active and brain-penetrating T-type calcium channel blocker.


As a result of our agreement with Santhera Pharmaceuticals, Idorsia will be entitled to milestone and sales payments as the company brings vamorolone to patients with Duchenne Muscular Dystrophy.

Furthermore, with several unencumbered assets in clinical development, additional contract revenue from partnerships and/or out-licensing remains an option for us.

Financial information

Read our latest financial reports and updates on how we will achieve sustainable profitability.

Our Innovation

Innovating from the lab bench all the way through to the patient’s bedside. Learn more about how we innovate, our portfolio and our target diseases.

Latest news

Our innovation is the basis for our long-term sustainability. Read the latest news from across our portfolio.

4. Discover

In addition to several drug candidates in the early stages of clinical and preclinical development, we must continue with our discovery efforts, to maintain a steady supply of innovative compounds to our pipeline. We aim to create a pipeline with a sales potential of at least CHF 5 billion.

“Our approach: novel projects that answer medical problems in groundbreaking ways, balanced with less risky projects where we have a deep understanding of the disease mechanisms.”

— Martine Clozel, CSO

5. Innovate

We integrate computational tools and digital technologies at various stages of the drug discovery, development, and commercialization process, so as to maximize our potential and bring breakthrough medicines to patients.

We look for creative ways to harness advances in technology to focus on novel targets and use new drug development methods. All functions involved in drug discovery and in clinical and pharmaceutical development are streamlined to assist in the delivery of tailored, high-quality medicines.

“We must integrate computational tools and digital technologies at every stage of the drug discovery, clinical development and commercialization process in order to maximize our potential to bring breakthrough medicines to patients.”

— André C. Muller, CEO

Drug discovery

  • Artificial intelligence
  • Computer modeling

Clinical development

  • Patient reported outcome measures
  • Creative clinical endpoints


  • Digital & social media
  • Advanced analytics

More joy –
The spark of passion


We want our employees to feel proud of their work, and of the company they work for. We provide a supportive and stimulating environment for high-performing teams, recognizing and rewarding their contributions.

“Achieving our strategic priorities is dependent on a company-wide effort, so we must attract, retain, and develop a talented and engaged workforce. ”

— André C. Muller, CEO